Diamyd Medical AB (publ) (STO:DMYD.B)
Sweden · Delayed Price · Currency is SEK 1.172
-0.068 (-5.48%)
May 21, 2026, 12:53 PM CET
Diamyd Medical AB Company Description
Diamyd Medical AB (publ) develops therapies for the treatment of autoimmune diabetes.
The company develops Diamyd, an antigen-specific immunotherapy diabetes vaccine, which is in phase IIb clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes; and Remygen, an oral regenerative and immunomodulatory drug candidate, which is in phase I/II clinical trial for the treatment of autoimmune and type 2 diabetes.
The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013.
Diamyd Medical AB (publ) was incorporated in 1984 and is based in Stockholm, Sweden.
Diamyd Medical AB (publ)
| Country | Sweden |
| Founded | 1984 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 41 |
| CEO | Anders Essen-Möller |
Contact Details
Address: Kungsgatan 29 Stockholm Sweden | |
| Phone | 46 86 61 00 26 |
Stock Details
| Ticker Symbol | DMYD.B |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | September - August |
| Reporting Currency | SEK |
| ISIN Number | SE0005162880 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Anders Essen-Möller M.Sc. | Chief Executive Officer |
| Niklas Axelsson | Chief Financial Officer |
| Martina Widman | Chief Operating Officer |
| Anton Lindqvist | Chief Scientific Officer |
| Sofia Mayans | Head of Manufacturing Site |